MediWound (NASDAQ:MDWD) Announces Quarterly Earnings Results, Misses Expectations By $0.01 EPS

MediWound (NASDAQ:MDWD) announced its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.01), Zacks reports. MediWound had a negative net margin of 180.30% and a negative return on equity of 67.22%. The firm had revenue of $3.09 million for the quarter, compared to analyst estimates of $2.59 million.

Here are the key takeaways from MediWound’s conference call:

• EscharEx’s VALUE Phase III trial remains on track, with interim sample-size reassessment and enrollment completion targeted by the end of Q1 2027. The company says nearly all of the approximately 40 sites are recruiting.
• MediWound expanded its estimated U.S. peak annual sales opportunity for EscharEx to $1.05 billion after including pressure ulcers, and plans to start a 50-patient diabetic foot ulcer study and a small pressure-ulcer investigator-initiated study in Q4 2026.
• NexoBrid’s U.S. commercial adoption continued to improve, with Vericel reporting record quarterly revenue, hospital unit sales and ordering centers; approximately 80 U.S. burn centers have ordered the product since launch.
• The new master service agreement with Vericel is expected to begin contributing revenue in the second half of 2026, including development programs targeting blast and friction injuries. MediWound reaffirmed 2026 revenue guidance of $24 million–$26 million, weighted heavily toward the second half.
• Financial performance weakened in the first half: Q2 revenue fell to $3.1 million from $5.7 million year over year, while cash and deposits declined to approximately $36 million from $54 million at year-end 2025 after $20 million of first-half cash burn. R&D spending is expected to remain elevated as the VALUE trial advances, and expanded-facility commercial supply is not expected until the second half of 2027.

MediWound Price Performance

Shares of NASDAQ MDWD traded down $0.38 during mid-day trading on Thursday, hitting $13.53. The company had a trading volume of 62,264 shares, compared to its average volume of 63,044. The stock has a market cap of $173.86 million, a price-to-earnings ratio of -5.99 and a beta of 0.15. MediWound has a 12 month low of $13.46 and a 12 month high of $20.30. The firm’s 50 day simple moving average is $14.36 and its two-hundred day simple moving average is $15.99.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on MDWD. Wall Street Zen upgraded MediWound from a “strong sell” rating to a “sell” rating in a report on Saturday, May 30th. Weiss Ratings restated a “sell (d-)” rating on shares of MediWound in a research note on Friday, July 17th. Oppenheimer reaffirmed an “outperform” rating and issued a $32.00 price objective (down from $33.00) on shares of MediWound in a report on Wednesday, May 27th. Finally, HC Wainwright reiterated a “buy” rating and set a $36.00 target price on shares of MediWound in a research note on Thursday, May 28th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, MediWound currently has an average rating of “Hold” and an average price target of $34.00.

Insider Transactions at MediWound

In related news, Director David Morton Fox acquired 3,537 shares of the stock in a transaction that occurred on Monday, June 1st. The stock was purchased at an average cost of $14.11 per share, for a total transaction of $49,907.07. Following the purchase, the director directly owned 22,283 shares in the company, valued at $314,413.13. This represents a 18.87% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link. 9.20% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On MediWound

Several hedge funds and other institutional investors have recently modified their holdings of MDWD. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in MediWound by 22.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company’s stock valued at $85,000 after purchasing an additional 999 shares during the last quarter. Rhumbline Advisers raised its holdings in shares of MediWound by 4.4% during the first quarter. Rhumbline Advisers now owns 11,316 shares of the biopharmaceutical company’s stock valued at $176,000 after buying an additional 481 shares during the last quarter. Russell Investments Group Ltd. boosted its position in shares of MediWound by 69.1% during the second quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 649 shares during the period. Marshall Wace LLP acquired a new position in shares of MediWound during the second quarter worth approximately $317,000. Finally, The Manufacturers Life Insurance Company grew its holdings in MediWound by 104.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 26,062 shares of the biopharmaceutical company’s stock worth $505,000 after buying an additional 13,312 shares in the last quarter. Institutional investors and hedge funds own 46.83% of the company’s stock.

MediWound Company Profile

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.